Frontlight ResearchEarly access
Active, not recruitingPhase 1/2
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
Key facts
- Who runs it
- Virginia Commonwealth University
- Where
- Richmond, United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1/2
- People taking part
- 80 people, planned
- Started
- 21 Nov 2022
- Expected to end
- Nov 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Intestinal Microbiota Transplant (IMT) Capsules
- Placebo Capsules
- Record updated
- 24 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (30)Hide the full registry criteria
Who can take part
- ->18 years of age
- Advanced liver disease
- Able to give written, informed consent
- Alcohol as a cause of advanced liver disease
- Continued sustained drinking
- Having previously declined a referral to traditional AUD therapy services or having failed such treatments
Who cannot take part
- Clinically significant use of illicit drugs
- Adverse event attributable to prior IMT
- Recent or current alcoholic hepatitis
- Uncontrolled mood disorders or primary psychotic conditions
- Unclear diagnosis of chronic liver disease
- known untreated, in-situ luminal GI cancers
- chronic intrinsic GI diseases (ulcerative colitis, Crohn's disease or microscopic colitis, eosinophilic gastroenteritis and celiac disease)
- History of aspiration, gastroparesis, intestinal obstruction
- Severe anaphylactic food allergy
- acute illness or fever on the day of planned FMT
- Other conditions which make patients are poor candidate for this study per investigator judgement
- WBC count<1000
- allergy to ingredients Generally Recognized As Safe in the G3 capsules (glycerol, sodium chloride, hypromellose, gellan gum, titanium dioxide, theobroma oil)
- Lack of sustained drinking
- Alcohol withdrawal symptoms
- MELD score>17
- Current hepatic encephalopathy on lactulose and/or rifaximin
- Non-elective hospitalization within last month
- on dialysis
- Dysphagia within 2 weeks
- Ongoing absorbable antibiotic use
- ASA Class IV or V
- Pregnant or nursing patients
- Immunosuppression
Where in United States
- Hunter Holmes McGuire VA Medical CenterRichmond, United States
- Virginia Commonwealth UniversityRichmond, United States
About the trial
What the trial wants to find out
The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.
The 2 groups in the trial
- Intestinal Microbiota Transplant capsulesTreatment being tested
Capsules will be provided twice during the trial
Treatment: Intestinal Microbiota Transplant (IMT) Capsules
- Placebo capsulesPlacebo, for comparison
Capsules will be provided twice during the trial
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Intestinal Microbiota Transplant in Alcohol-Associated Chronic Liver Disease and Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Record updated
- 24 August 2026